Optimal treatment for metastatic HER2+ breast cancer.
APA
Tolaney SM (2026). Optimal treatment for metastatic HER2+ breast cancer.. Clinical advances in hematology & oncology : H&O, 24(2), 106-108.
MLA
Tolaney SM. "Optimal treatment for metastatic HER2+ breast cancer.." Clinical advances in hematology & oncology : H&O, vol. 24, no. 2, 2026, pp. 106-108.
PMID
41996679
같은 제1저자의 인용 많은 논문 (5)
- Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.
- Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data.
- Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
- Sacituzumab Govitecan for Triple-Negative Breast Cancer. Reply.
- Understanding first-line treatment patterns and survival outcomes across sociodemographic groups of women with metastatic triple-negative breast cancer in the United States: a real-world study.